2024-03-18 - CD Munich - ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE v. Healios K.K et al. - UPC_CFI_80/2023

Was ist diese UPC-Entscheidung?

Zusammenfassung: The judge-rapporteur (Kupecz) issued an Order following the interim conference in Astellas' revocation action against Healios / Osaka University concerning EP 3 056 564 (induced pluripotent stem cells). On parallel-proceedings coordination, the Defendants — after being asked — declined to have the UPC revocation stayed pending the EPO opposition outcome, so the oral hearing was confirmed for 26 June 2024. The Court admitted Claimant's second declaration D21, with a short-reply window for Defendants (similar length, strictly in reply, possibly including a short rebuttal expert report) until 11 April 2024. Value of proceedings under Rule 104(j) in conjunction with Rule 152.3 RoP was set at EUR 4 M, corresponding to a EUR 400,000 ceiling under the AC scale (Art. 69 UPCA). The Court reiterated that the AC ceiling is only a cap — recovery presupposes reasonable and proportionate costs supported by itemised hours × role × task × rate information.

Quelle und Fundstellen

Quelle: https://www.unified-patent-court.org/en/node/620

Referenz: ORD_598256/2023

Aktenzeichen: UPC_CFI_80/2023